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Exosomes from Hepatitis C Infected Patients Transmit
HCV Infection and Contain Replication Competent Viral
RNA in Complex with Ago2-miR122-HSP90
Terence N. Bukong., Fatemeh Momen-Heravi., Karen Kodys, Shashi Bala, Gyongyi Szabo*
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
Antibodies targeting receptor-mediated entry of HCV into hepatocytes confer limited therapeutic benefits. Evidence
suggests that exosomes can transfer genetic materials between cells; however, their role in HCV infection remains obscure.
Here, we show that exosomes isolated from sera of chronic HCV infected patients or supernatants of J6/JFH1-HCV-infected
Huh7.5 cells contained HCV RNA. These exosomes could mediate viral receptor-independent transmission of HCV to
hepatocytes. Negative sense HCV RNA, indicative of replication competent viral RNA, was present in exosomes of all HCV
infected treatment non-responders and some treatment-naı¨ve individuals. Remarkably, HCV RNA was associated with Ago2,
HSP90 and miR-122 in exosomes isolated from HCV-infected individuals or HCV-infected Huh7.5 cell supernatants. Exosome-
loading with a miR-122 inhibitor, or inhibition of HSP90, vacuolar H+-ATPases, and proton pumps, significantly suppressed
exosome-mediated HCV transmission to naı¨ve cells. Our findings provide mechanistic evidence for HCV transmission by
blood-derived exosomes and highlight potential therapeutic strategies.
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Introduction
Hepatitis C virus (HCV) infection is one of the leading causes of
liver disease with over 170 million individuals chronically infected
worldwide [1,2]. Severe complications including fibrosis, cirrhosis,
and hepatocellular carcinoma are among the long-term effects of
HCV infection, making liver transplantation the ultimate choice of
treatment for advanced liver disease [3]. Even with successful liver
transplantation, patients face eminent HCV re-infection of the
newly transplanted liver. Recent therapies with anti-HCV E1-E2
or other neutralizing antibodies that attempted to block HCV
transmission achieved only limited success [4–7].
HCV is a positive-sense single-stranded RNA enveloped virus of
the Flaviviridae family. The 9.6 kb HCV genomic RNA encodes a
single polypeptide that is proteolytically cleaved to structural (core,
E1, and E2) and non-structural (p7, NS2, NS3, NS4A, NS4B,
NS5A and NS5B) HCV viral proteins [8]. The HCV viral
envelope E1 and E2 proteins engage numerous host cell proteins
for viral entry including CD81 [9–11]. CD81 interaction with
HCV E1/E2 is critical in HCV entry and anti-CD81 or anti-E1/
E2 antibodies have been shown to block HCV virus entry [7,12].
Given the importance of these viral envelope proteins in regulating
HCV infection, numerous immune therapies have been developed
to specifically target and/or neutralize HCV envelope proteins
[7,13–15]. Targeted antibody therapies have offered limited
success in preventing liver allograft infection by HCV. Recently,
a potent human-derived monoclonal antibody was demonstrated
to effectively prevent and treat HCV1 infection in chimpanzees
[7]. However, the same antibody was not completely effective in
humans [7], raising the possibility of other mechanisms of virus
entry into hepatocytes. Previous reports have suggested receptor
independent transmission of HCV [6,16], though the precise
mechanisms or possible therapeutic strategies remain to be
explored.
Exosomes are a subpopulation of extracellular vesicles that
originate from multivesicular bodies (MVBs), ranging from 40–150
nm in size and are produced by most cell types. These vesicles can
be detected in blood, urine, and other body fluids [17]. Exosomes
can modulate signal transduction, antigen presentation to T-cells,
and transmission of genetic material between cells [18]. Over the
past decade, a great body of evidence shows that exosomes can be
secreted into the extracellular space and can mediate indirect cell-
to-cell communication by transferring bio macromolecules,
functional proteins, and RNAs between cells [19,20].
HCV infection occurs via cell free virus and direct cell-to-cell
transmission [6]. Indirect cell-to-cell transmission is another
pathway to consider. Previously, HCV viral RNA has been
identified in supernatant of HCV-SGR cells [21] and exosome-like
structures have been detected in the supernatant of HCV infected
cells [22] and in the plasma of HCV-infected patients [23].
Recently, Dreux et al (2013) showed that HCV-RNA-containing
exosomes can mediate transfer of RNA to co-cultured plasmacy-
toid dendritic cells (pDCs) and trigger the production of type I
interferon (IFN) in vitro [24].
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Here we tested the hypothesis that exosomes derived from HCV
infected hepatocytes or from the sera of HCV infected patients
carry viral RNA and exploit the cellular exosomal delivery system
to mediate receptor-independent HCV transmission to hepato-
cytes. We found that exosomes derived from HCV infected
Huh7.5 cells and HCV infected patients contained HCV RNA
that induced active infection in primary human hepatocytes
(PHH). These exosomes were rich in replication-competent HCV-
RNA in complex with miR-122, Ago2, and HSP90; and mediated
HCV transmission independent of CD81, SB-RI and APOE.
Mechanistically, functional inhibition of miR-122, HSP90 or
modification of cellular micro-environmental pH using a vacuolar-
type H+-ATPase (V-ATPase) and proton pump inhibitor significantly
suppressed the capacity of exosomes to mediate HCV transmission.
Results
Separation of HCV infected exosomes from free HCV
viruses and characterization of exosomes
Given our interest to investigate the capacity of exosomes
derived from HCV J6/JFH-1-infected Huh7.5 cells and serum of
HCV infected patients to mediate active transmission, we had to
efficiently separate exosomes from the free HCV virus. Because
HCV virions and exosomes have very similar sizes and densities,
the traditional ultracentrifugation and sucrose gradient isolation
method is insufficient for isolating pure exosomes free of virus
contamination. To overcome this limitation, we optimized a
CD63 immuno-magnetic isolation method to purify exosomes
from cell culture supernatants of HCV J6/JFH-1 infected Huh7.5
cells and sera of HCV infected patients. Briefly, after serial
filtration (1 mm, 0.44 mm and 0.22 mm) of supernatants, exosomes
were initially isolated using Exoquick. To further purify exosomes
and exclude other microparticles or free HCV contamination,
Exoquick-isolated exosomes were subjected to immuno-magnetic
selection with CD63, a selection marker of exosomes. This
protocol was verified by analysis for other exosomal markers by
western blotting (CD9 and CD81), electron microscopy, and
Nanoparticle tracking analysis (NTA) (Figures S1A, S1B & S1C).
The Exoquick-CD63 immuno-magnetic selection procedure
recovered more exosomes compared to, ultracentrifugation-
CD63 immuno-selection of exosomes (Fig. 1A & 1B); based on
this observation we used the Exoquick followed by CD63
immuno-magnetic selection for subsequent experiments. We
observed that in a fixed total volume there were significantly
more free HCV viral particles compared to the number of
exosome particles in HCV J6/JFH-1 infected Huh7.5 cell
supernatants [approximately 7:1 ratio] and in HCV infected
patient serum samples [approximately 4:1 ratio] (Fig. 1C). We also
found higher HCV viral copy numbers in the free virus fraction
compared to exosomes in J6/JFH-1 infected Huh7.5 cell
supernatants (Fig. 1D) and HCV patients’ serum (Fig. 1E). Purified
exosomes were analyzed by transmission electron microscopy,
demonstrating their vesicular shape and size range between 50 and
100 nm (Figure S1A). Further analysis with NanoSight demonstrated
comparable histogram size plots of exosomes from culture super-
nantants of HCV J6/JFH-1 infected Huh7.5 cells and exosomes from
serum of HCV infected patients (Figure S1B & S1C).
To rule out exosome contamination with free HCV virus, we
carried out a simulation experiment mixing cell free HCV virus
with uninfected exosomes from Huh7.5 cell culture supernatants
for 24 h and re-isolated exosomes with Exoquick followed by
CD63 immuno-selection or ultracentrifugation followed by CD63
immuno-selection. The uninfected exosomes exposed to free HCV
virus showed no detectable HCV viral RNA while HCV RNA was
present in the flow through following immuno-magnetic CD63
selection of exosomes (Fig. 2A & 2B). Further characterization of
exosomes and free virus showed that isolated exosomes contained
Apolipoprotein B (APOB) which was not present in cell free HCV
viruses (Fig. 2C). Apolipoprotein E (APOE) was found to be
associated to a large extent with HCV virus fraction and
significantly lower in exosomes compared to cell free virus
fractions (Fig. 2D). These observations suggest that our purified
exosomes were to a large extent devoid of lipo-viral contamina-
tion. RNase H treatment to destroy free RNA in the cell free virus
concentrate and isolated exosomes from HCV infected Huh 7.5
cells failed to prevent transfer of HCV infection to naı¨ve cells, thus
ruling out the possibility of envelope free viral RNA mediating
HCV infection. These data indicate that both HCV derived
exosomes and HCV virus are resistant to RNase treatment similar
to the previous report [25] and still cause productive infection even
after RNase treatment (Figure S2).
Exosomes from serum of HCV infected patients or HCV
J6/JFH-1 infected Huh7.5 cells contain HCV RNA,
miR-122, Ago2, and HSP90
First, we established efficient methods for exosome purification
using Exoquick followed by CD63-based isolation as described
above. These exosomes were devoid of free HCV virus
contamination as detailed. Exosomes isolated from sera of some
HCV-infected patients or supernatants of HCV J6/JFH1 infected
Huh7.5 cells contained comparable HCV RNA content for the
same number of free HCV viral particles compared to the same
number of HCV exosome particles (Fig. 3A). These observations
allowed us to use the same number of infectious HCV viral
particles and HCV exosomes for subsequent experiments.
Treatment-naı¨ve and non-responder (interferon plus ribavirin)
patients with active HCV infection had detectable HCV RNA in
serum-derived exosomes (Fig. 3B). In contrast, treatment respond-
ers, who cleared HCV infection, showed no detectable HCV in
exosomes (Fig. 3B). Additionally, interferon alpha treatment of
Huh7.5 cells had no effect on the number of exosomes released
from hepatocytes (Figure S3) compared to untreated cells.
Recent studies have consistently demonstrated that miR-122,
Ago2, and HSP90 enhance HCV replication [26–30]. We found
Author Summary
Since its first isolation and identification in 1989, Hepatitis
C virus (HCV), has caused significant disease burden to
humans worldwide. So far, there is no vaccine against HCV,
and neutralizing antibody therapies to block receptor–
mediated transmission of HCV to liver cells have so far
achieved limited therapeutic benefits. This indicates that
HCV can transmit infection via receptor-independent
mechanisms. Evidence suggests that small host extracel-
lular vesicles (exosomes) can mediate receptor-indepen-
dent transfer of genetic material between cells, though
their role in HCV transmission remains uncertain. Here, we
found that the HCV virus can utilize host exosomes to
transmit infection to naı¨ve liver cells, even in the presence
of potent blocking anti-HCV receptor antibody treatments.
Additionally, we identified alternative treatment strategies
that can block host exosomes from transmitting HCV
infection. Our study provides novel insights to an
alternative mechanism of HCV transmission that can
compromise anti-HCV immune therapies and proposes
potential therapeutic approaches to block exosome-
mediated transmission of HCV infection.
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that HCV J6/JFH-1 infected Huh7.5 cells produced exosomes
that are enriched in Ago2 and contain barely detectable HSP90
protein compared to control exosomes from Huh7.5 cells
(Fig. 3C). Interestingly, exosomes from HCV infected treatment-
naı¨ve and treatment non-responder individuals, but not treatment
responders, were rich in Ago2 and HSP90 (Fig. 3D) compared to
control healthy uninfected individuals. GW182 a RISC complex
protein which we recently identified as an enhancer of HCV
replication associated with alcohol use [31], was not detected in
exosomes in our experimental conditions.
Micro RNA-122, a host factor utilized by HCV for replication,
was present in exosomes isolated from both HCV J6/JFH-1
infected Huh7.5 cells and HCV-infected individuals (Fig. 3E &
3F). We observed that exosomes from HCV J6/JFH-1 infected
Huh 7.5 cells showed higher levels of miR-122 compared to
exosomes from non-infected cells (Fig. 3E), while exosomes from
HCV-infected patients contained lower miR-122 levels compared
to those from healthy controls (Fig. 3F).
Exosomes from HCV treatment naı¨ve patients or culture
supernatants of HCV J6/JFH-1 infected Huh7.5 cells
transmit HCV infection
Exosomes were recently shown to mediate retroviral infection
independent of envelope protein-receptor interaction [32]. More
recently, exosomes from Huh7.5 infected cells were found to
induce type I interferon production in dendritic cells [24].
Observation of the presence of HCV RNA in exosomes
prompted us to evaluate if exosomes from J6/JFH-1-infected
hepatocytes or from HCV infected individuals could transmit
infection to uninfected cells. We found that exosomes derived from
supernatants of HCV J6/JFH-1 infected Huh7.5 cells mediated
HCV infection after co-culture with uninfected Huh 7.5 cells
(Fig. 4A and Figure S4) which could be inhibited by Telaprevir
(VX-950) an NS3.4A serine protease inhibitor (Fig. 4B). Further,
exposure of primary human hepatocytes (PHH) to exosomes isolated
from treatment-naı¨ve or treatment non-responder HCV infected
patients resulted in effective virus infection and replication as indicated
by detectable HCV RNA in the culture supernatants (Fig. 4C). Active
virus replication after infection of PHH with HCV exosomes was
indicated by a 2–3 log increase in HCV copy numbers in PHH at
48 hours after infection compared to the initial HCV copy numbers
introduced by the HCV exosomes used for induction of infection
(Fig. 4D). Additionally, the use of Telaprevir (VX-950), an NS3.4A
serine protease inhibitor, could inhibit HCV replication caused by free
virus and HCV exosomes in infected PHH (Fig. 4E).
Exosomes mediate CD81, SB-RI and APOE receptor-
independent transmission of HCV
CD81, SB-RI, APOE and HCV E1/E2 proteins are important
host and viral molecules for HCV infection [33]. We and others
have shown that anti-CD81 and anti-HCV E1/E2 antibodies can
block HCV infection [7,12,34]; however, in some instances
antibody therapy in patients could not fully prevent HCV
infection [16]. Based on these observations, we tested whether
the presence of anti-CD81 antibodies would block exosome and
cell free virus transmission of HCV. We found that anti-CD81 pre-
treatment effectively blocked free HCV virus infection of target
Huh7.5 cells, indicated by significantly low HCV RNA expression
(Fig. 5A) and by lack of expression of HCV NS3 protein (Fig. 5B).
However, exosomes containing HCV RNA could still transmit
HCV infection despite anti-CD81 antibody pre-treatment (1:50
dilution) (Fig. 5A & 5B). These findings were validated in primary
human hepatocytes where anti-CD81 pre-treatment significantly
inhibited free HCV virus infection but failed to prevent patient
exosome-mediated HCV transmission (Fig. 5C & 5D). Addition-
ally, SB-RI (Fig. 5E) or APOE (Fig. 5F) antibody pre-treatment
could block HCV J6/JFH-1 free virus transmission but not HCV-
exosome transmission of HCV to naı¨ve Huh7.5 cells (Fig. 5E &
5F).
We next tested CD81-deficient Huh7.25-CD81 cells [35] and
found that HCV exosomes could still mediate HCV transmission
but infection rate with the free virus entry was significantly
diminished (Fig. 6A). In the parental Huh7.0 cells, both exosomes
and free HCV virus resulted in comparable extent of HCV
infection (Fig. 6B). HCV E1 and E2 envelope glycoproteins which
can modulate HCV infection [36] have been shown to associate
with exosomes [23], thus we tested if anti-HCV E2 antibody
treatment could block HCV transmission by exosomes. We found
that anti-HCV E2 antibody treatment of HCV J6/JFH-1 virus
could significantly block HCV transmission by free HCV particles
but not by exosomes (Fig. 6C).
Exosomes derived from HCV infected patient serum and
Huh7.5-HCV J6/JFH-1 cells contain replication-competent
HCV RNA in complex with Ago2-miR-122
Recent reports have demonstrated the role of Ago2 and miR-
122 in enhancing HCV replication when bound to the 59-UTR of
HCV dsRNA [26]. We observed that the same MOI of free HCV
viruses or HCV-exosomes resulted in a trend (but not statistically
significant) of greater HCV transmission by exosomes compared to
the cell free virus (Fig. 5). Based on this observation, we surmised
that exosomes might contain replication-competent RNA in
association with RISC complex proteins that could enhance
HCV RNA stability and enhance viral replication [26,37,38].
Using RNA-chromatin immunoprecipitation (RNA-ChIP) analysis
of exosomes isolated from HCV J6/JFH-1 infected Huh 7.5 cells
or HCV infected patients after Ago2 pull-down, we found that
Ago2 was associated with miR-122 (Fig. 7A), positive sense HCV
RNA (Fig. 7B upper panel) and, in some cases, negative sense
HCV RNA (Fig. 7B lower panel). Using free HCV virus RNA and
RNA from HCV infected cells we confirmed primer specificity for
detection of positive and negative sense HCV RNA (Figures S5A
Figure. 1. Assessing the efficiency of exosome isolation protocol. (A) Schematic experimental flow chart to compare the efficiency of two
exosome isolation methods from cell culture supernatants, Exoquick+CD63 immuno-magnetic selection and ultracentrifugation+CD63 immuno-
magnetic selection for recovery of exosomes. (B) Exosomes were isolated by either Exoquick+CD63 immuno-magnetic selection or
ultracentrifugation+CD63 immuno-magnetic. Isolated exosomes were quantified using Nanosight (NTA). (C) Total CD63 selected exosomes and
cell free HCV virus was isolated from cell culture supernatants of HCV J6/JFH-1 infected Huh7.5 cells and HCV infected serum as detailed in the
methods. Total number of exosomes and HCV viral particles isolated were quantified using NanoSight. Data is expressed as fold comparison for three
independent repeat cell culture experiments and 5 serum samples from HCV infected patients. (D) Total RNA was extracted from total culture
supernatants of HCV J6/JFH-1 infected Huh7.5 cells, flow through samples (free HCV virus) and CD63 selected exosomes (HCV exosomes) and
analysed for HCV RNA content by quantitative real-time PCR. (E) Total RNA was extracted from HCV infected patient serum, flow through (free HCV
patient virus) and CD63 selected HCV patient exosomes and analysed for HCV RNA content by quantitative real-time PCR. Results are representative
of 4 repeat experiments and 6 HCV infected patient samples expressed as mean + SEM with p,0.05 considered statistically significant using ANOVA
analysis and Mann-Whitney U test using GraphPad prism 5.0 software.
doi:10.1371/journal.ppat.1004424.g001
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Figure 2. Simulation study ruling out viral carryover of cell free HCV virus and purity of isolated exosome. (A) Comparative schematic
flow diagram of exosome isolation by Exoquick and ultracentrifugation with additional CD63 immuno-magnetic selection. (B) Control uninfected
exosomes were mixed with free HCV virus suspension and after 24 hour co-culture, samples were divided into two portions for (1) total RNA
extraction or (2) immuno-magnetic CD63 isolation of the exosomes followed by total RNA extraction. Extracted RNA was analysed for HCV RNA
content by quantitative real-time PCR. Results are representative of 4 indipendent experiments. (C &D) Exosomes and free HCV virus were isolated as
detailed in our methods. Equal numbers of isolated exosomes and free HCV virus were then lysed in RIPA protein extraction buffer. Extracted total
protein from exosomes and cell free virus as indicated was subjected to APOE and APOB ELISA analysis according to the manufacturers’ protocol.
Results are representative of 3 independent experiments with p,0.05 considered statistically significant usisng ANOVA analysis with GraphPad prism
5.0 software.
doi:10.1371/journal.ppat.1004424.g002
HCV Transmission by Exosomes
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Figure 3. Exosomes from HCV J6/JFH-1 infected Huh7.5 cells and sera of HCV infected patients contain HCV RNA, miR-122, Ago2,
and HSP90. Total RNA was extracted from the same number of infectious virus and exosome particles using QIAzole (Qiagen) for lysis then spiked
with equal amounts of synthetic C. elegans (cel)-miR-39 and after this step total RNA was extracted using Zymo research Direct-zol RNA MiniPrep kit.
100 ng of total (cell or exosome) RNA was reverse transcribed to cDNA and analysed for HCV RNA using SYBR Green quantitative real-time PCR
analysis. Comparative delta-delta ct method was used for determining relative HCV RNA using Cel-miR-39 RNA as normalizing control. (A) HCV RNA
expression was analysed in total RNA extracted from HCV J6/JFH-1 virus, HCV exosomes from J6/JFH-1 infected Huh7.5 cell supernatants, free HCV
patient virus and HCV patient exosomes. Equal amounts of exogenouse synthetic cel-miR-39 was spiked into each sample during RNA extraction
which was later used as normalization control for HCV RNA fold comparison using comparative delta-delta ct method. (B) HCV RNA relative content in
the exosomes were measured in different study groups using equal number of serum exosomes from healthy controls, HCV infected treatment naive,
HCV infected treatment reponders, and HCV infected treatment non-responder patients determined by quantitative real-time PCR. Equal amounts of
HCV Transmission by Exosomes
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& S5B). Additionally, using co-immuno precipitation, we con-
firmed that HSP90 and Ago2 formed complexes within the HCV
containing exosomes likely providing further stabilization of the
HCV RNA-replication complex (Fig. 7C) [39].
These striking observations indicate that serum exosomes from
some HCV infected treatment-naı¨ve patients contain positive
sense RNA of HCV virus and are able to transmit active HCV
infection. We found that, even in the few patients where we could
not detect viral RNA in the exosomes due to the limitation of the
sensitivity of the Real Time PCR method (Table 1 & 2), HCV
infection of PHH was still evident (Fig. 4C). Furthermore,
replication competent, negative sense HCV RNA was also present
in some treatment-naı¨ve and in all non-responder patients
(Table 1 & 2).
Inhibition of miR-122 or HSP90 blocks exosome-
mediated transmission of HCV in Huh7.5 cells
Given that exosomes from HCV-infected treatment-naı¨ve and
treatment non-responders contained Ago2 in complex with miR-
122, and HSP90, we tested the effect of miR-122 or HSP90
inhibitors which have been suggested for HCV treatment
[29,37,40]. Delivery of a miR-122 inhibitor resulted in about
50% reduction in miR-122 levels in Huh7.5 cells that is significant
considering the high abundance of miR-122 in hepatocytes
(Fig. 8A). However, inhibition of miR-122 in Huh7.5 cells prior
to infection with HCV exosome failed to significantly suppress
HCV transmission (Fig. 8A). Given that exosomes harbored HCV
in complex with miR-122/HSP90, we hypothesized that miR-122
in the exosomes provides advantages for HCV transmission. To
test this hypothesis, we transfected HCV-exosomes with a miR-
122 inhibitor or control, washed and re-purified the miR-122
inhibitor- or control inhibitor-loaded HCV-exosomes and used
them for infection of naı¨ve Huh7.5 cells. The miR-122 inhibitor-
loaded HCV-exosomes resulted in a significant reduction in
intracellular miR-122 levels in Huh7.5 cells (Fig. 8B). Importantly,
we found reduced virus transmission by HCV-exosomes loaded
with the miR-122 inhibitor as indicated by decreased HCV NS3
protein compared to the controls (Fig. 8C).
We also assessed the potential of the HSP90 activity inhibitor,
17-DMAG, or HSP90 siRNA treatment to modulate HCV
infection transmitted by exosomes (Fig. 8D). We found that
DMAG treatment but not HSP90 siRNA treatment could
significantly block exosome-mediated HCV transmission
(Fig. 8D).
Vacuolar-type H+-ATPase inhibitor and proton pump
inhibitor can block exosome and free virus transmission
of HCV to Huh7.5 cells
Previous data showed that viral HCV entry and subsequent
infection can be prevented by administering vacuolar-type
H+-ATPase inhibitor [41]. Moreover, Meertens et al [42]
reported that entry of HCV pseudoparticles (HCVpp) was effi-
ciently blocked by bafilomycin A1, a specific vacuolar-type H+-
ATPase inhibitor, which neutralizes the pH in early endosomes
and injures progression of endocytosis beyond this level. Exosome
entry through endocytosis is reported to be pH dependent in the
traffic of tumor exosomes in regulating both their release and
uptake by tumor cells [43]. Based on these reports, we set up an in
vitro model utilizing a vacuolar-type H+-ATPase inhibitor
(bafilomycin A1) or a proton pump inhibitor (Lansoprazole) to
study the role of low pH in favoring HCV infected exosome
uptake in Huh 7.5 cells. We found that low pH plays a role in the
entry of infected exosome into the Huh 7.5 cells and infection by
HCV infected exosomes can be blocked using vacuolar-type H+-
ATPase or a proton pump inhibitor. Our data show that both
Lansoprazole (Fig. 9A & 9B) and bafilomycin A1 (Fig. 9C & 9D)
could significantly inhibit HCV transmission by exosomes and cell
free HCV viruses to Huh7.5 hepatoma cells in a dose-dependent
manner without causing significant cellular cytotoxicity (Figures
S6A & S6B).
Discussion
Exosomes are found in different biofluids and represent a small
(40–150 nm) subpopulation of extracellular vesicles of endocytic
origin released by almost all cell types. They act as natural carriers
of genetic materials, namely miRNA, mRNA and proteins
[44,45]. Notably, exosomes have been shown to mediate disease
transmission caused by bacteria, infectious prion protein, and
viruses [46,47]. In the context of HCV, recent studies showed that
hepatocyte-derived exosomes containing viral RNA induced
production of IFN-a in plasmacytoid dendritic cells (pDCs) in
vitro [24]. In this study, we demonstrate that circulating exosomes
derived from sera of treatment-naı¨ve HCV infected individuals or
HCV treatment non-responder individuals contain HCV virus
that can transmit active HCV infection to primary human
hepatocytes, confirmed with the observation of a 2–3 log increase
in HCV copy numbers in PHH compared to the initial HCV copy
numbers in exosomes used for infection indicated virus replication.
A recent study also reported exosome-mediated transmission of
HCV in Huh7.5 cells [48]. Our observations confirmed and
extended a recent report that also found that exosomes derived
from HCV J6/JFH-1 infected Huh7.5 cells can shuttle virus to
normal Huh7.5 cells and establish a productive infection. Using a
stringent isolation methodology of serial filtration followed by
density separation and immune magnetic CD63-positive exosome
isolation, we optimized a method of HCV exosome isolation
without carryover of free virus thereby further underscoring the
capacity of exosomes to transmit HCV infection.
Our findings showed for the first time that exosomes from sera
of HCV infected patients or culture supernatants of HCV J6/JFH-
1 infected Huh7.5 cells can mediate effective CD81, SB-RI, HCV
E2 and APOE -independent HCV transmission to hepatocytes. A
recent report by Ramakrishnaiah et al [48] indicated that
exosomes can mediate partial CD81-independent HCV transmis-
sion in Huh7.5 cells, however in that study cell free HCV
transmission could not be fully excluded. Our results indicate that
exosomes that are devoid of free virus contamination are capable
of HCV transmission even in the presence of a potent anti-CD81,
exogenouse synthetic cel-miR-39 was spiked into each sample during RNA extraction which was later used as normalization control for HCV RNA fold
comparison using comparative delta-delta ct method. (C) 50 mg of protein was used for western-blot analysis of whole cell lysates of Huh7.5 cells,
HCV J6/JFH-1 infected Huh7.5 cells, exosomes from Huh7.5 cell supernatants, and exosomes from HCV J6/JFH-1 infected Huh7.5 cell supernatants. (D)
Western-blot analysis of exosomal proteins from HCV patients’ serum. (E) miR-122 expression of exosomes from Huh7.5 cell supernatants and
exosomes from HCV J6/JFH-1 infected Huh7.5 cell supernatants. Equal amounts of exogenouse synthetic cel-miR-39 was spiked into each sample
during RNA extraction from exosomes and was later used as normalization control for HCV RNA fold comparison using comparative delta-delta ct
method (F) miR-122 profile of exosomes from HCV patient serum samples were analysed by real-time quantitative PCR and using exogenous cel-miR-
39 RNA for normalization. Data are expressed as mean + SEM, p,0.05 was considered statistcally significant by Mann-Whitney U test.
doi:10.1371/journal.ppat.1004424.g003
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Figure 4. Exosomes from HCV J6/JFH-1 infected Huh7.5 cells transmit HCV infection to the human hepatoma cell line (Huh7.5 cells)
and exosomes from HCV infected patients’ serum transmit HCV infection to primary human hepatocytes. (A) Exosomes from HCV J6/
JFH-1 infected Huh7.5 cell culture supernatants were co-cultured with Huh7.5 cells for 12 h alongside appropriate controls. Exosomes were then
HCV Transmission by Exosomes
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anti-SB-RI, anti-HCV E2 and anti-APOE antibody treatment and
in CD81-deficient cells. These observations could explain in part
why neutralizing antibodies or therapies that target host/viral
protein interactions at the level of cell entry can be compromised
and likely occur via cell-to-cell transmission by exosomes.
Given that infections with HCV-exosomes compared to the
same MOI of free HCV virus particles, showed a tendency for
higher levels of HCV transmission to hepatocytes, it was unclear if
these exosomes contained replication competent HCV RNA,
factors that enhanced virus replication or facilitated mechanisms of
exosomes entry to target cells. Recently, reports have consistently
demonstrated that RISC-like complexes involving Ago2 and miR-
122 can protect the HCV 59 internal ribosome entry site (59 IRES)
and enhance HCV replication [26,38]. We found higher miR-122
expression in HCV J6/JFH-1 infected Huh7.5 cells derived
exosomes compared to HCV infected patient exosomes and their
respective controls, possibly as a result of suppressed interferon
production in Huh7.5 cells since Huh7.5 cells harbor a mutation
in the dsRNA sensor retinoic acid-inducible gene-I (RIG-I) [49–
51]. However, using RNA ChIP analyses we found that exosomes
from HCV J6/JFH-1 infected Huh 7.5 cells and exosomes from
the two patient groups that have active infection, treatment-naı¨ve
and treatment non-responders, showed increased proportion of
miRNA-122 in complex with Ago2. Additionally, it was remark-
able that Ago2 and miR-122 bound to the HCV 59-UTR was also
in association with HSP90 which has been shown to stabilize
RISC complexes [52] and potentially increase HCV replication.
Our observations support a hypothesis whereby exosomes mediate
higher HCV transmission because they contain replication-
competent viral RNA, as well as, known HCV replication
enhancers- Ago2 [26], miR-122 [26,29,37], and HSP90
[37,53,54]. Additionally, HCV RNA in exosomes might mediate
higher levels of infection possible due to the higher stability of
HCV RNA when associated with Ago2 and miR-122 as suggested
by Shimakami et al [39].
The presence of host proteins within HCV-exosomes is a clever
strategy by the virus to ensure effective replication once in the
endoplasmic reticulum (ER) given that the ER does not contain
these exosomal proteins [55]. Our novel findings may translate
and offer possible clinical implications to HCV treatment
resistance with interferon/ribavirin given that exosomes from
HCV-infected treatment resistant patients contained HCV nega-
tive sense RNA, which is mostly associated with replication-
competent HCV RNA. Strikingly, only some of the treatment-
naı¨ve patients with HCV positive-sense RNA detected in their
exosomes contained negative-sense HCV RNA (Table 2). Impor-
tantly, none of HCV treatment responder patients harbored
detectable HCV RNA in their serum-derived exosomes consistent
with their status of HCV viral clearance. The implication of our
findings needs additional clinical follow-up to determine whether
treatment and/or disease outcome using anti-HCV immune
therapies would be influenced by the composition of serum-
derived exosomes in HCV infected patients.
Based on our novel findings that exosomes can mediate virus
transmission via CD81, SB-RI and APOE -independent mecha-
nisms potentially compromising the efficacy of HCV immuno-
therapies, we next aimed to test therapeutic alternatives. We
analyzed the potential use of miR-122 inhibition and DMAG
treatment both of which have been successfully explored for HCV
treatment but not yet assessed in the context of exosome-mediated
HCV transmission. We found that using an exosome targeted
miR-122 inhibitor system or the HSP90 inhibitor, DMAG, which
could inhibit the effective function of these host factors which
modulate HCV infection/replication, could significantly suppress
HCV transmission by exosomes. Strikingly, attenuation of HSP90
or miR-122 levels by siRNA knockdown and miR-122 inhibitor in
target cells was not sufficient to inhibit HCV transmission via
exosomes. This could be due to the fact that HCV exosomes
contain all the necessary viral and host protein factors that are
otherwise not present in the endoplasmic reticulum [18], and can
thus mediate effective replication once cellular entry is accom-
plished by exosome uptake.
Since exosomes originate from lumen of multivesicular bodies
(MVBs), their release and uptake are associated with the endocytic
pathway [56]. Acidification of intracellular organelles is reported
to be fundamental to the function of the endocytic pathways and
exosomes uptake [57]. The vacuolar H+-ATPases (V-ATPases)
and proton pumps are responsible for generating and maintaining
intra-cellular pH gradients across cell membranes. Disruption to
their functions were reported to be accompanied by lysosomal
dysfunction and impaired endocytosis [58,59]. From another
perspective, several reports show a crucial role of low pH and
endosome acidification for triggering virus entry, not addressing
the distinction between exosomes and cell free viruses [41,60].
Here we show that the use of bafilomycin A1, a specific vacuolar
H+-ATPase proton pump inhibitor, and Lansoprazole, a proton
pump inhibitor, prevented the capacity of exosomes and cell free
virus to transmit infection, suggesting their use in the treatment
regimens for HCV infection. This usage seems to be more
influential as it is reported that the intracellular pH was not
washed off and replaced with fresh medium and cells were cultured for another 24 h. Culture supernatant from these exosome-infected Huh7.5 cells
were then transferred to naı¨ve Huh7.5 cells and cultured for 24 h. Total RNA was extracted from cells and analyzed for HCV RNA by quantitative real-
time PCR. (B) Huh7.5 cells were co-cultured with free HCV virus or HCV exosomes with an MOI of 1 for 6 h after which viruses or exosomes were
washed off and replaced with fresh complete culture medium. Cells were the cultured further or not over the time period indicated followed by
treatment or not with Telaprevir (VX-950) at concentrations/time indicated. At indicated time points total RNA was extracted from cells and analyzed
by Real time quantitative PCR for HCV RNA (C) Serum exosomes were isolated from three different patient groups (treatment naı¨ve, treatment non-
responders, and treatment responders) and co-cultured with primary human hepatocytes (PHH) for 8 h. Exosomes were then washed off and
replaced with fresh medium for a further 40 hours. Culture supernatants obtained from PHH were analyzed for HCV RNA by quantitative real-time
PCR. (D) Serum exosomes were isolated from HCV infected treatment naive patients using anti-CD63 immuno magnetic selection and co-cultured
with primary human hepatocytes (MOI of 1 of infectious HCV viral particles or infectious HCV-exosome particles was used). Total RNA extracted from
exosomes and PHH 48 h post infection and analysed by real-time quantitative PCR analysis for HCV RNA levels. Input exosome samples were
appropriately matched by using 100 ng of total input exosome RNA and 100 ng of total infected cell RNA for HCV RNA comparison after infection to
allow valid comparison of the starting exosome preparation. (E) Free HCV virus and CD63 selected HCV exosomes were isolated from HCV infected
patient sera and used to infect primary human hepatocytes over the indicated time course (MOI = 1). Following infection cells were treated or not
with Telaprevir (VX-950) at concentrations indicated for 24 h or not as indicated. Total RNA was then extracted from cells and analysed for HCV RNA
using quantitaive real time PCR. Results are representative of exosomes from 4 different HCV infected treatment naive patients. Data are expressed as
mean + SEM, p,0.05 was considered statistically significant by Mann-Whitney U test.
doi:10.1371/journal.ppat.1004424.g004
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Figure 5. Exosomes from HCV J6/JFH-1 infected Huh7.5 cells and HCV patients mediate effective HCV transmission in the presence
of anti-CD81, anti-SB-RI or anti-APOE antibody. (A&B) Huh7.5 cells were infected with HCV J6/JFH-1 virus or with exosomes from culture
supernatants of HCV J6/JFH-1 infected Huh7.5 cells with CD81 antibody pre-treatment (1:50 dilution) or not as indicated. Viruses and exosomes were
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noticeably changed by dosages less than 100 nM of bafilomycin
A1 and for a short period of time (4 h), which is reported to be the
critical time point for effect of bafilomycin A1 to prevent viral
entry [61].
In summary, our novel findings, illustrated in Figure 10 provide
mechanistic insights into how exosomes can mediate indirect cell-
to-cell viral receptor independent transmission of HCV. Further-
more, we provide evidence that circulating exosomes of HCV
infected patients can infect primary human hepatocytes. Addi-
tionally, our findings further support the rationale for using miR-
122 inhibitors, HSP90 inhibitor, and potentially proton-pump and
Vacuolar-type H+-ATPase inhibitors to prevent exosome-mediat-
ed HCV transmission.
Materials and Methods
Cell lines, primary human hepatocytes (PHH) and HCV
J6/JFH-1 virus
Huh7.5, Huh7.0 (a gift from Dr. Charlie Rice, Rockefeller
University, New York) and CD81-deficient Huh7.25 [a gift from
Dr. Takaji Wakita (National Institute of Infectious Disease, Tokyo,
Japan) and Dr. T. Jake Liang (NIDDK, National Institutes of
Health, USA)] cells were cultured as previously described [35,49]
with slight modification, using exosome depleted FBS (System
Bioscience cat. #EXO-FBS-50A-1). Primary human hepatocytes
were obtained from the National Institutes of Health (NIH) liver
tissue cell distribution system (LTCDS; Minneapolis, MN, USA;
Pittsburgh, PA; Richmond, VA, USA), which was funded by NIH
contract #N01-DK-7-004/HHSN2670070004C and from BD
Bioscience. Highly infectious and replication competent HCV J6/
JFH-1 virus (genotype 2a) were generated as previously described
[62]. The pFL-J6/JFH-1 plasmid used for virus generation was
provided by Dr. Charlie Rice and Dr. Takaji Wakita (National
Institute of Infectious Disease, Tokyo, Japan). HCV J6/JFH-1 virus
concentration in culture supernatants was determined using Nano-
Sight LM10 (MOI of infectious viral particles or infectious exosomes)
and by quantitative real-time PCR as previously described [37].
Ethics statement
Subjects were recruited from the Hepatology clinic at the
University of Massachusetts Medical School. This research
protocol was reviewed by the Committee for the Protection of
Human Subjects in Research at the University of Massachusetts
Medical School (IRB #2284). All subjects who donated samples
for this project provided signed written informed consent. Subjects
were assessed for baseline demographics, Hepatitis C viral serology
and liver function parameters (Table 1). Healthy control subjects
had no evidence of systemic disease, HCV infection, or other liver
diseases. Informed consent was obtained from all subjects. Blood
samples were drawn and serum samples were analyzed for HCV
RNA using RT-PCR and processed as subsequently indicated.
Exosome isolation and purification from cell lines and
patient samples
Huh7.5 cells and HCV J6/JFH-1 infected Huh7.5 cells were
maintained in DMEM low glucose medium supplemented with
10% exosome depleted FBS and 1% penicillin/streptomycin
(Gibco, cat. #15140-163). Cell culture supernatants following cell
infection or not, or patient serum samples were collected,
centrifuged at 2500 rpm for 10 mins at 4uC to remove cell debris,
then filtered through a 0.2 mm filter. The 40 mL of filtered culture
supernatant for exosome isolation was concentrated to a final
1 mL volume using the Amicon Ultra-15 Centrifugal Filter Unit
with Ultracel-100 membrane (Millipore, cat. #UFC910024).
Concentrated culture supernatants or filtered patient serum
(500 uL) were mixed with the appropriate volume of Exoquick-
TC reagent (System Biosciences cat. #EXOTC10A-1) or
Exoquick (System Bioscience cat. #EXOQ5A-1) respectively, for
exosome isolation according to the manufacturers’ specification.
Samples were gently mixed and incubated for 1 h at 4uC.
Following incubation, exosomes were precipitated by centrifuga-
tion at 1400 rpm for 10 mins at 4uC. The recovered exosomes
were re-suspended in 16phosphate buffered saline (PBS). Positive
selection of exosomes was done using anti-CD63 immuno-
magnetic capturing with primary anti-CD63 antibody (Abcam
cat. #ab8219 and Santa Cruz cat. #15363) followed by
corresponding secondary antibody coupled to magnetic beads
(Miltenyi Biotec cat. #130-048-602). The Miltenyi Biotec
MidiMACS separator was used with LD columns (cat. # 130-
042-901) for exosome isolation.
Electron microscopy
Exosomes isolated by positive anti-CD63 immuno-magnetic
bead selection were re-suspended in PBS and transferred to a
formvar-coated copper grid then allowed to settle/attach for
30 minutes. The grid was washed by sequentially positioning
droplets of PBS on top and using absorbing paper in between. The
samples were then fixed by drop-wise addition of 2% paraformal-
dehyde onto parafilm and placing the grid on top of the
paraformaldehyde drop for 10 min. Fixation was followed by five
washes with deionized water and samples contrasted by adding
2% uranyl acetate for 15 minutes. Afterward, the samples were
embedded by adding a drop of 0.13% methyl cellulose and 0.4%
uranyl acetate for 10 minutes. The grid was visualized using a
Philips CM10 transmission electron microscope and images were
captured using a Gatan CCD digital camera.
Quantification of HCV-exosomes, purified HCV infectious
virus particles and HCV RNA copy numbers
Quantification of immuno-magnetic CD63 bead captured
infectious HCV J6/JFH-1-exosomes and HCV J6/JFH-1 virus
preparations was determined using NanoSight LM10 system
(NanoSight, Amesbury, UK) equipped with a fast video capture
washed off after 8 h of co-culture and fresh medium was added to cells followed by 40 h further culture at 37uC. Total RNA and protein was then
extracted from cells and analyzed by (A) quantitative RT-PCR for HCV RNA and by (B) western blotting for HCV NS3 protein. (C & D) Primary human
hepatocytes were infected with either serum exosomes or free HCV viruses from HCV treatment naı¨ve patients; exosomes from Huh7.5-HCV J6/JFH-1
culture supernatants; HCV J6/JFH-1 virus along with anti-CD81 antibody pre-treatment for one hour before infection or not as indicated for 48 h.
Total RNA and protein was then extracted from cells and analysed for HCV RNA by quantitative RT-PCR and by western blot for HCV NS3 protein. An
MOI of 1 of infectious HCV virus and infectious HCV-exosomes were used for all infections. (E&F) Huh7.5 cells were infected with either HCV J6/JFH-1
exosomes or free HCV J6/JFH-1 viruses for 48 h after prior treatment of cells with anti-SB-RI antibody (1:50 or 1:100 dilution) (Fig. 5E) or anti-APOE
antibody (1:50 dilution) (Fig. 5F) at concentrations indicated for one hour before infections. Total RNA and protein was then extracted from cells and
analysed for HCV RNA by quantitative RT-PCR and by western blot for HCV NS3 protein. An MOI of 1 of infectious HCV virus and infectious HCV-
exosomes were used for all infections. Results presented are representative of 3 independent experiments expressed as mean + SEM, p,0.05 was
considered statistically significant by Mann Whitney U test or ANOVA analysis for multiple comparisons performed with GraphPad Prism Version 5.0.
doi:10.1371/journal.ppat.1004424.g005
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Figure 6. CD81 deficiency or anti-HCV E2 antibody treatment does not block effective HCV transmission by exosomes. (A) CD81
deficient Huh7.25 and (B) Huh7.0 cells were infected with HCV J6/JFH-1 virus or exosomes from culture supernatants of HCV J6/JFH-1 infected Huh7.5
cells as indicated. Viruses and exosomes were washed off after 8 h of co-culture and fresh medium added to the cells and cultured at 37uC for
another 40 h. Total RNA was then extracted from cells and analysed for HCV RNA by RT-qPCR. An MOI of 1 of infectious HCV virus and infectious HCV-
exosomes were used for all infections. Input exosome samples were appropriately matched by using 100 ng of total input exosome RNA and 100 ng
of total infected cell RNA for HCV RNA comparison after infection to allow valid comparison. (C) Huh7.5 cells were infected with HCV J6/JFH-1 virus or
with HCV exosomes from culture supernatants of HCV J6/JFH-1 infected Huh7.5 cells with anti-HCV E2 antibody pre-treatment (1:50, 1:100 dilutions)
or not as indicated. Viruses and exosomes were washed off after 8 h of co-culture and fresh medium was added to cells followed by 40 h further
culture at 37uC. Total RNA and protein was then extracted from cells and analyzed by quantitative RT-PCR for HCV RNA. Results presented are
representative of 3 independent experiments expressed as mean + SEM, p,0.05 was considered statistically significant by Mann Whitney U test or
ANOVA analysis for multiple comparisons performed with GraphPad Prism Version 5.0.
doi:10.1371/journal.ppat.1004424.g006
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and Nanoparticle Tracking Analysis (NTA) system, according to
the manufacturer’s instructions. Quantification of HCV RNA
copy numbers was done as previously described [31].
siRNA and miRNA inhibitor constructs and cell
transfections
The following siRNA and miRNA inhibitors were used: human
HSP90 siRNA (Santa Cruz cat. #sc-35608); control siRNA (Santa
Cruz cat. #sc-44236), hsa-miR-122 anti-miR miRNA Inhibitor
(Ambion, Austin, Tx cat. #AM11012) and anti-miR Negative
Control (Ambion, Austin, Tx cat.#AM17010). miRNA or control
inhibitors were complexed with the liver specific in vivo Altogen
delivery reagent (Altogen Biosystems cat. #5060) which was
loaded into control exosomes or HCV exosomes then co-cultured
with target cells as indicated. Specific SiRNA or control siRNA
was complexed with FugeneHD (Roche cat. # 04709705001) and
transfected into target cells according to the manufacturer’s
specifications as indicated.
RNA Chromatin immunoprecipitation (ChIP) and
co-immunoprecipitation analysis of exosome samples
Exosomes isolated from cell culture supernatants or patient
serum samples were fixed at room temperature with 4%
formaldehyde buffered saline. Afterward, exosomes were lysed in
SDS ChIP lysis buffer (Millipore cat. # 20-163) supplemented
with protease inhibitor and RNase inhibitor. Total exosome
proteins were pre-cleared with protein G beads. 50 mg of total
protein was incubated with Ago2 antibody. Immunoprecipitation
was performed for 90 minutes at 4uC using 10 mg/ml primary
Ago2 antibody and normal rabbit IgG (Santa Cruz cat # sc-2027)
non-specific antibody used as IP control. A mixture of Protein A/
G PLUS-Agarose beads (Santa Cruz cat. #sc-2003) was added,
and the incubation was continued for an additional 60 minutes.
The samples were washed with SDS ChIP lysis buffer supple-
mented with protease inhibitor and RNase inhibitor. The
immunoprecipitated protein-RNA complex was either used for
Western blot analysis or RNA purification after Ago2 pull down
using the Zymo research Direct-zol RNA MiniPrep kit (cat.
#R2050), according to the manufacturer’s specification. TaqMan
MicroRNA assay was used for quantification of miRNA, using a
CFX Connect Real-Time PCR Detection System (Philadelphia,
USA). The exosome miRNA data was normalized to Cel39 and
fold change was calculated using delta-delta ct method as
previously described [63].
Western blot analysis
Western blots were performed using the following established
protocols. Briefly, proteins were resolved on 10% SDS-PAGE gels.
After electrophoresis resolved proteins were transferred onto
nitrocellulose membranes. Following protein transfer, membranes
were blocked for 1 hour in PBS containing 5% non-fat dry milk
and 0.1% Tween-20. Blots were then incubated overnight with
primary antibody at 4uC. The following primary antibodies were
used: anti-HCV NS3 (Abcam cat. #ab13830); anti-HSP90 (Cell
Signaling cat. #4874); anti-CD63 (Abcam cat. #ab8219 used for
western blotting and Santa Cruz Biotechnology cat. #sc-15363
used for exosomes purification); anti-Ago2 (Sigma cat.
#SAB4200274); anti-CD81 (Santa Cruz Biotechnology cat. #sc-
23962), normal rabbit IgG-AC antibody (Santa Cruz Biotechnol-
ogy cat. # sc-2345); anti-beta actin [Ac-15] (Abcam, cat.
#ab6276). The membranes were then incubated for 1 hour with
horseradish peroxidase-conjugated secondary antibodies (dilution
1:10,000) that included: goat anti-mouse IgG-HRP (Santa Cruz
Biotechnology cat. #sc-2005); goat anti-rabbit IgG-HRP (Santa
Cruz Biotechnology cat. #sc-2004). Finally, the proteins were
visualized with the Clarity Western ECL substrate (BioRad, cat.
#170-5061) chemiluminescence system according to the manufactur-
er’s protocol using the Fujifilm LAS-4000 luminescent image analyzer.
Quantification of miRNA or HCV RNA expression in
exosomes and cell lines
Prior to total RNA isolation, equal volume of plasma (500 mL)
or 500 uL of 10 mL concentrated culture supernatant samples
were thawed on ice, mixed with QIAzole (Qiagen), vortexed and
Figure 7. Exosomes from Huh7.5 cells and HCV infected patients’ sera harbor replication competent HCV RNA and RISC complexes
that enhance HCV infection. RNA ChIP analyses of Ago2 complexes in exosomes isolated either from culture supernatants of HCV J6/JFH-1
infected Huh7.5 cells or from patient samples were subjected to Ago2 pull down then total RNA isolation which was analyzed for (A) miR-122
expression, (B) for HCV positive (B-upper panel) and negative (B-lower panel) sense RNA by PCR. (C) Immunoprecipitation of Ago2 and HSP90
complexes from exosomal protein lysate isolated from culture supernatants of HCV J6/JFH-1 infected Huh7.5 cells or from patient serum samples.
Normal rabbit IgG non-specific antibody was used as IP control antibody. Experiments are representative of 3 independent repeats for cell culture
supernatants and patient samples (HCV patient genotypes 1a, 1b, 2a, and 3b).
doi:10.1371/journal.ppat.1004424.g007
Table 1. Clinical parameters of HCV patients used for serum miRNA isolation.
Parameters Distribution
Gender: Male/female 30/28
Age 54.07 6 1.92
Viral load (IU/mL) 56104 – 9.36106 (HCV patients only)
Genotype 1a, 1b, 2b, 3a (HCV patients only)
Patient numbers in each Category Healthy Control: 12
HCV treatment responders:6
HCV treatment responders:6
HCV Treatment non responders: 6
doi:10.1371/journal.ppat.1004424.t001
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Table 2. HCV RNA content of patient exosomes.
HCV RNA content of patient exosomes Positive sense HCV RNA Negative sense HCV RNA
Control patients None None
HCV infected treatment Naive 14 out of 34 7 out of 34 (all 7 had positive sense HCV RNA)
HCV treatment Responders 0 out of 6 0 out of 6
HCV Treatment non-responders 6 out of 6 6 out of 6
doi:10.1371/journal.ppat.1004424.t002
Figure 8. HCV transmission by exosomes can be blocked by miR-122 or HSP90 functional inhibition within exosomes. (A) miR-122
inhibitor or control inhibitor complexed with Altogen liver specific in-vivo delivery reagent was co-cultured with Huh7.5 derived control exosomes for
20 mins and exosomes re-purified to exclude carryover of transfection reagent. The derived exosome containing miR-122 inhibitor or control
inhibitor was co-cultured with Huh7.5 cells for 12 h. Post miR-122 inhibition or not using loaded exosomes for delivery, cells were washed and
infected with HCV exosomes as indicated (MOI of 1 of infectious HCV-exosome particles was used) for 24 h. Total RNA and proteins was then
extracted from cells and analyzed for miR-122 by RT-qPCR and western blot analysis for HCV NS3 with B-actin serving as a loading control. (B) miR-122
inhibitor or control inhibitor complexed with Altogen liver specific in-vivo deliver reagent was co-cultured with HCV exosomes for 20 mins and
exosomes re-purified. HCV exosomes loaded with miR-122 inhibitor or not as indicated were then transferred unto Huh7.5 cells and co-cultured for
24 h in complete tissue culture medium. Following HCV exosome infection co-cultures as indicated, total protein was extracted from Huh7.5 cells and
analyzed for (C) HCV NS3 protein. (D) Western blot analyses of HCV NS3 and HSP90 proteins 48 h after HSP90 siRNA or DMAG pre-treatment (1 h) and
24 h after co-culture with exosomes from HCV J6/JFH-1 infected Huh7.5 cell culture supernatants. An MOI of 1 was used for all HCV exosome
infections. Data presented here is representative of 3–4 independent experiments with p,0.05 considered to be statistically significant by Mann
Whitney U test or ANOVA for multiple comparison performed with GraphPad Prism Version 5.0.
doi:10.1371/journal.ppat.1004424.g008
HCV Transmission by Exosomes
PLOS Pathogens | www.plospathogens.org 15 October 2014 | Volume 10 | Issue 10 | e1004424
incubated at RT for 5 mins. Synthetic C. elegans (cel)-miR-39 was
spiked and after this step total RNA was extracted using Zymo
research Direct-zol RNA MiniPrepKit as per instructions. Taq-
Man miRNA Assay (Applied Biosystems) was used to analyze the
miRNA from serum or plasma samples. Cel-miR-39 was used to
normalize the technical variation between the exosomes samples
and when comparing miRNA or HCV RNA content in cell lines
compared to exosomes. Quantification of miR-122 was performed
using Taqman microRNA assays (Applied Biosystems). RNU48
was used as an endogenous control for miR-122 expression in cells
and Cel-miR-39 was used as an exogenous control to normalize
for technical variation in RNA isolation for determining miR-122
levels in exosomes.
Analysis of HCV positive and negative sense RNA
After RNA isolation as indicated, reverse transcription was
performed by two different methods both of which were designed
to amplify the 59-UTR of HCV as previously described [37].
Briefly, positive sense RNA was amplified involving a first cDNA
synthesis reaction using 500 ng of total RNA using the Bio-Rad
cDNA synthesis kit according to the manufacturer’s specification.
The positive sense HCV 59 UTR was then amplified using
the following primer sequence: HCV Forward Primer:
59-TCTGCGGAACCGGTGAGTAC-39; HCV Reverse primer:
59-TCAGGCAGTACCACAAGGCC-39. HCV negative sense
RNA was detected using primers and PCR conditions as
previously described [64].
Figure 9. HCV transmission by exosomes and free virus can be blocked by proton pump inhibitor (Lansoprazole) and Vacuolar-
type H+-ATPase inhibitor (bafilomycin A1). (A&B) Huh 7.5 cells were pre-treated with Lansoprazole (2.5 mg/ml, 5 mg/ml, and 10 mg/ml) for 1 h at
indicated concentrations, and then infected with (A) HCV exosomes or (B) cell free HCV virus for 24 h. Total protein was then extracted from cells and
analyzed for HCV NS3 protein. (C&D) Huh 7.5 cells were pre-treated with bafilomycin A1(Baf A1) (12.5 nM, 25 nM, 50 nM, and 100 nM) for one hour at
concentrations indicated, then infected with (C) HCV J6/JFH-1 exosomes or (D) cell free HCV virus for 24 h. Total RNA was then extracted from cells
and analyzed for HCV RNA. An MOI of 1 of HCV-exosomes and cell free HCV virus were used for all infections. Data presented here is representative of
3 independent experiments with p,0.05 considered to be statistically significant by Mann Whitney U test.
doi:10.1371/journal.ppat.1004424.g009
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Vacuolar-type H+-ATPase inhibitor (bafilomycin A1), proton
pump inhibitor (Lansoprazole) and for inhibition of HCV
Huh 7.5 cells derived exosomes and virus entry/replication
Bafilomycin A1 was purchased from Sigma Aldrich and the
proton pump inhibitor; Lansoprazole (Prevacid 24 hr OTC,
Novartis), was purchased over the counter. Lansoprazole was
dissolved in DMSO and applied to Huh7.5 cells at concentrations
of 2.5 mg/ml, 5 mg/ml, and 10 mg/ml. Telaprevir (VX-950) was
purchased from Selleckchem and used as previously described
[65]. One hour later, HCV virus suspension and HCV infected
exosomes (captured with CD63) were added to the cells. Twenty-four
hour later, the cells were washed 3 times and assessed for viral
structural protein, NS3. Bafilomycin A1 was dissolved in DMSO and
applied to the Huh 7.5 cells at concentrations of 12.5 nM, 25 nM,
50 nM, and 100 nM, while the concentration of DMSO in the final
treatments was 0.01%. One hour later, HCV virus suspension and
HCV infected exosomes (captured with anti-CD63 antibody) were
added to the cells. After 24 h, the cells were washed 3 times and
assessed for viral RNA entry.
Lactate dehydrogenase (LDH) assay
The LDH toxicity assay kit (Abcam Cat. # ab65393) was used
according to the manufacturer’s specification. Briefly, released
LDH in culture supernatants of Huh7.5 cells after 24 h co-culture
with different concentration of Bafilomycin A1 and Lansoprazole
was measured as the indicator of lysed cells. The percentage of
cytotoxicity was measured by subtracting LDH content in
remaining viable cells from total LDH in untreated controls.
Staurosporine (20 nM) (Abcam, Cambridge, MA) treatment of
Huh7.5 cells for 12 h was used as positive control. The final
absorbance was measured at 490 nm. All experiments were
performed in triplicate.
Blocking antibody experiments
Cells, as indicated, were treated with blocking antibodies to
target HCV host receptors for one hour prior to infection with
either HCV exosomes, HCV J6/JFH-1 virus or not as indicated.
Blocking antibodies used included: anti-CD81 antibody (Santa
Cruz Biotechnology cat. # sc-23962), anti-Scavenging Receptor
Figure 10. Schematics of exosome mediated HCV transmission and possible therpaeutic strategies. HCV infected hepatocytes form
multivesicular bodies (MVB) by taking up bits of the cytoplasm and its contents (proteins [HSP90], miRNA [miR-122] and RNAs [HCV RNA]) into
membrane-bound vesicles. These MVB in HCV infected hepatocytes then fuse with the plasma membrane and release their contents, including
numerous small vesicles (exosomes), outside the cell. Exosomes released from HCV infected hepatocytes contain replication competent HCV RNA in
complex with miR-122, Ago2, and HSP90. Further, exosomes released from HCV infected hepatocytes are capable of CD81-independent HCV
transmission to a naı¨ve hepatocyte. The use of HSP90, miR-122, proton pump and Vacuolar-type H+-ATPase inhibitors can significantly limit the
capacity of HCV transmission by exosomes.
doi:10.1371/journal.ppat.1004424.g010
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(SR-BI) antibody (Abcam, cat. # ab52629), anti-HCV E2
antibody (GeneTex cat. # GTX103353) and anti-ApoE antibody
(Millipore Cat. #: AB947).
Enzyme-Linked Immunosorbent Assay (ELISA) for APOE
and APOB
Culture supernatants of Huh7.5 cells infected or non-infected
with HCV (J6/JFH-1) were centrifuged at 1,0006 rpm for
10 minutes to remove cells followed by another spin at 2,0006
rpm for 15 minutes to remove cellular debris. Exosomes were
positively selected with CD63 immunomagnetic beads as de-
scribed above and the flow through collected which included cell
free virus and viral particles. Levels of APOE and APOB proteins
in the exosomes were identified by using Apolipoprotein E (APOE)
Human ELISA Kit (Abcam cat # ab108813) and Human
Apolipoprotein B (APOB) Quantikine ELISA Kit (R&D Systems
cat # DAPB00) according to the manufacturers’ protocols. The
same number of control exosomes (obtained from non-infected
Huh 7.5 cells), exosomes derived from HCV infected Huh 7.5 cells
and viral particles were used for the experiment and quantified by
Nanosight measurements. The optical density of the color
reactions for both plates was read on plate reader at 450 nm.
Standard curves were generated and concentrations of APOE and
APOB were calculated as stipulated in the manufacturer’s
protocol. Liver cell protein lysate was used as positive control.
Statistical analysis
Data are representative of at least 3 independently repeated
experiments presented as mean + standard error of the mean
(SEM). A non-parametric Mann-Whitney U test and multiple
comparisons for repeated-measures were done using ANOVA
performed with GraphPad Prism Version 5.0 (GraphPad Soft-
ware). A p value of ,0.05 was considered significant.
Supporting Information
Figure S1 Size distribution of CD63 immuno-isolated
exosomes. (A) Electron micrograph of CD63 positively selected
exosomes from culture supernatants of Huh7.5 cells representing a
size range from 50 nm to 100 nm. (B) Histogram plot of exosomes
isolated from Huh7.5 cell culture supernatants were analyzed
using NanoSight. (C) Histogram plot of exosomes isolated from
sera of HCV infected patients were analyzed using NanoSight.
Both exosomes derived from Huh7.5 cells and patients’ sera were
in the range of 50–100 nm. Data presented here is representative
of 3 independent experiments.
(TIF)
Figure S2 Free HCV virus and HCV exosomes are
resistant to RNase treatment. Free HCV virus, HCV
CD63-immuno-selected exosomes and culture supernatant of
HCV J6/JFH-1infected Huh7.5 cells were treated with RNase
H (1 IU/ml &5 IU/ml) for 30 min then co-cultured with the
naı¨ve Huh7.5 cells as indicated. Total RNA was then extracted
from cells 48 h after infection and assessed for HCV RNA by real-
time quantitative PCR. Results are representative of 3 indepen-
dent experiments.
(TIF)
Figure S3 Type 1 interferon does not modulate exosome
release from hepatocytes. Huh7.5 cells were treated with
different concentrations of interferon alpha as indicated over 48 h.
Culture supernatants were then recovered and total exosomes
isolated as decribed in the methods and quantified using Nano-
Sight. Results are representative of 3 independent repeat
experiments.
(TIF)
Figure S4 Exosomes from HCV infected Huh 7.5 cells
can transmit HCV to the naive Huh 7.5 cells. Cell free
supernatants from HCV-exosome infected Huh7.5 cells for
conditions indicated above were used to infect Huh7.5 cells for
24 h alongside appropriate controls. Cells were then analyzed by
western blot for HCV NS3 protein. Results are representative of 3
independent experiments.
(TIF)
Figure S5 Specificity of HCV positive and negative
sense RNA detection. (A&B) Total RNA was extracted from
free HCV virus and HCV J6/JFH-1 infected Huh7.5 cells. Total
RNA was then reverse transcribed to cDNA using BioRad iScript
cDNA Synthesis Kit. Using specific PCR conditions, as detailed in
the methods, end point PCR products were run on a 1% agarose
gel with ethidium bromide. Amplified PCR products were
visualised using the BioRad ChemiDoc XRS Gel Photo
Documentation System.
(TIF)
Figure S6 Lansoprazole and bafilomycin A1 LDH toxic-
ity assay. (A&B) Lansoprazole and bafilomycin A1 toxicity was
assessed in Huh7.5 cells after 24 h exposure at concentrations
administered to the cells, using the LDH assay kit from Abcam
according to the manufacturers specification. There was no
statistically significant difference between cytotoxicity induced by
different concentrations of bafilomycin A1(12.5 nM, 25 nM, and
50 nM) and untreated cells (p,0.001). There was no statistically
significant difference between cytotoxixity induced by different
concentration of Lansoprazole (5 mg/ml, 10 mg/ml and 50 mg/ml)
and untreated cells (p,0.001). Staurosporine (20 nM) was used as
a positive control and induced significant cell death. Results are
representative of 4 repeat experiments with p,0.05 considered
statistically significant by Mann Whitney U test.
(TIF)
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